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Aminoacyl-tRNA synthetase mutations have been linked to neurological diseases, but aminoacyla-
tion may be unaffected. This protein superfamily also performs many other diverse functions.
Yang et al. insightfully engineer a single mutation to unmask a cell signaling activity of tyrosyl-
tRNA synthetase [1].To begin with, this is fiction—and with
all powerful fictitious stories, we start
with a disclaimer: ‘‘Characters, places,
and incidents are either the product of
the author’s imagination or are used
fictitiously, and any resemblance to
actual entities, events, or locales is
entirely coincidental.’’ However, when
a story is truly compelling, we become
convinced that the disclaimer ismerely
masking the identity of real characters
and their environment.
The story is reminiscent of the tale of
Dr. Jekyll and Mr. Hyde [2], but is set
in the theater of proteins. In essence,
the leading character, Dr. Jekyll has
a well-defined and respected role in
a quite orderly intracellular environ-
ment. The rules, for all practical pur-
poses, are understood. Yet much be-
yond his control, Dr. Jekyll can be
transformed into Mr. Hyde, who
doesn’t honor precedent or adhere to
the rules and can even turn violent to
wreak havoc within the cell. Such is
the case for a series of neuropathies,
where genetic mutations have been
identified in tRNA synthetase genes
(Figure 1). Paradoxically, despite the
disease-causing mutation, Dr. Jekyll
may continue to faithfully supply ami-
noacylated tRNAs for protein synthe-
sis. Thus, we ask as the plot develops,
where is Mr. Hyde and what is his
role?
The leading character in this work is
played by tyrosyl-tRNA synthetase
(TyrRS). TyrRS is well recognized as a
conscriptedcomponent of protein syn-
thesis. However, TyrRS has adapted
to perform very different functions in
certain species. For example, in ad-
dition to its housekeeping role in trans-lation in the lower eukaryote Neuros-
pora crassa, TyrRS is an essential
RNA splicing factor [3]. In humans,
TyrRS plays a dual role in cell signaling
as a cytokine [4]. Its cytokine activity is
dependent on exposure of a buried
‘‘ELR’’ tripeptide motif that occurs
upon a specific proteolytic cleavage
event. So, if Mr. Hyde does not emerge
during protein synthesis, can he be
found lurking in any of these alternate
roles (Figure 2)?
The research group of Xiang-Lei
Yang and Paul Schimmel at The
Scripps Research Institute has intro-
duced a single mutation into human
TyrRS to unleash Mr. Hyde. Using
X-ray crystal structures and models
of humanTyrRS, themutationwas ratio-Chemistry & Biology 14, December 2007 ª2nally designed to expose the critical
‘‘ELR’’ motif that initiates a cascade
of signals within the cell. This single
mutation has little effect on the overall
protein structure. Its aminoacylation
activity is decreased, but remains ro-
bust for protein synthesis. In essence,
Dr. Jekyll is transformed into Mr. Hyde
and the mutant TyrRS cell signaling
behavior goes awry because the ELR
motif is now continuously exposed.
Within the cell, the mutant TyrRS
triggers uncontrolled endothelial cell
proliferation and migration. In animal
models, the mutant TyrRS becomes
proangiogenic. In short, a single muta-
tion has uncoupled regulation that bal-
ances the TyrRS’s secondary roles in
cell signaling.Figure 1. Evolution of the tRNA Synthetase Superfamily
Mutations confer new functions to a tRNA synthetase. Disease-causing mutations may affect
either the protein synthesis activity of the tRNA synthetase or its alternate functions.007 Elsevier Ltd All rights reserved 1307
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(A) The tRNA synthetases may be adapted for dual roles that coexist with their aminoacylation activity.
(B) Paralogs of tRNA synthetases and their domains can provide important nonaminoacylation functions within the cell.Now, this is a theoretical mutation
and thus the disclaimer at the begin-
ning. However, it represents a powerful
example that is reminiscent of a cast of
disease-causing tRNA synthetase mu-
tations which are poorly understood.
The mechanism of this ‘‘virtual’’ dis-
ease-inducing mutation will likely fore-
shadow many authentic genetic muta-
tions that are localized in the tRNA
synthetases. A number of these ge-
netic mutations have little impact on
aminoacylation activity, yet they pro-
foundly affect human health. These in-
cludemutations in TyrRS [5], as well as
GlyRS [6] in different versions of Char-
cot-Marie-Tooth disease. As another
example, a mutation in the amino
acid editing domain of mouse alanyl-
tRNA synthetase caused late onset of
neurological disease [7].
The family of tRNA synthetases has
adapted in very idiosyncratic ways to
perform many other roles in the cell1308 Chemistry & Biology 14, December 2that extend well beyond tRNA aminoac-
ylation (Figure 2). In some scenarios,
the tRNA synthetase moonlights in
the cell and maintains two jobs [8]. In
other cases, a tRNA synthetase pa-
ralog has wholly adapted for a new
role in this superfamily of proteins [9].
As Yang et al. have shown, it is the
nonaminoacylation roles that many of
these poorly understood tRNA synthe-
tase mutations may affect. Indeed, in
a twist of fate, Mr. Hyde will likely de-
fine and characterize new activities of
tRNA synthetases to add to a growing
list of diverse functions that have
already emerged.
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